EXAI NASDAQ

Exscientia plc is a pioneering pharmatech firm that leverages artificial intelligence (AI) to revolutionize drug discovery and development. The company provides a comprehensive, AI-driven platform that spans the entire drug development lifecycle. This integrated system supports crucial stages, including identifying disease targets, designing potential drug candidates, developing translational models, and optimizing patient selection for clinical trials. A key area of focus for Exscientia is the development of small molecule drug candidates. Through its advanced AI capabilities, the platform not only facilitates the efficient design of novel drug molecules but also employs AI-guided assessments to ensure patients receive the most suitable therapeutic interventions. Established in 2012, Exscientia plc is headquartered in Oxford, United Kingdom.